Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?

TY - JOUR

T1 - Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?

AU - Mayr, Christian Reinhard

AU - Kiesslich, Tobias

AU - Modest, Dominik Paul

AU - Stintzing, Sebastian

AU - Ocker, Matthias

AU - Neureiter, Daniel

N1 - [Kiesslich, Tobias; Mayr, Christian Reinhard; Neureiter, Daniel] Center for Physiology, Pathophysiology and Biophysics - Salzburg and Nuremberg, Institute for Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria;***Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (Salk), Salzburg, Austria***Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (Salk), Salzburg, Austria;g Cancer Cluster Salzburg, Austria

PY - 2022

Y1 - 2022

KW - EPITHELIAL-MESENCHYMAL TRANSITION

KW - OPEN-LABEL

KW - INTRAHEPATIC CHOLANGIOCARCINOMA

KW - MULTIDRUG-RESISTANCE

KW - METASTATIC CHOLANGIOCARCINOMA

KW - MOLECULAR-BASES

KW - MESSENGER-RNA

KW - SINGLE-ARM

KW - EXPRESSION

KW - CELLS

U2 - 10.1080/13543784.2022.2034785

DO - 10.1080/13543784.2022.2034785

M3 - Original Article

C2 - 35098846

SN - 1354-3784

VL - 31

SP - 221

EP - 233

JO - EXPERT OPINION ON INVESTIGATIONAL DRUGS

JF - EXPERT OPINION ON INVESTIGATIONAL DRUGS

IS - 2

ER -